Skip to main content

Leveraging Health Communication Research to Inform Regulation of Direct-to-Consumer Ads for Prescription Medications: a Comment on O’Donoghue et al.

This is a preview of subscription content, access via your institution.


  1. Wilkes MS, Bell RA, Kravitz RL. Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Aff. 2000; 19: 110-128.

    Article  CAS  Google Scholar 

  2. Huh J, DeLorme DE, Reid LN, An S. Direct-to-consumer prescription drug advertising: History, regulation, and issues. Minn Med. 2010; 93: 50-52.

    PubMed  Google Scholar 

  3. Mackey TK, Yagi N, Liang BA. Prescription drug coupons: Evolution and need for regulation in direct-to-consumer advertising. Research in Social & Administrative Pharmacy: RSAP. 2013. doi:10.1016/j.sapharm.2013.08.002.

    Google Scholar 

  4. Perri M 3rd, Shinde S, Banavali R. The past, present, and future of direct-to-consumer prescription drug advertising. Clin Ther. 1999; 21: 1798-1811. discussion 1797.

    Article  PubMed  Google Scholar 

  5. Talley CR. Direct-to-consumer prescription drug advertising. Am J Health-Syst Pharm: AJHP: Off J Am Soc Health-Syst Pharm. 1997; 54: 2181.

    CAS  Google Scholar 

  6. Vitry AI. Does direct-to-consumer prescription drug advertising do more harm than good? Ann Intern Med. 2009; 151: 823-824. author reply 824.

    Article  PubMed  Google Scholar 

  7. Schwartz LM, Woloshin S. Communicating uncertainties about prescription drugs to the public: A national randomized trial. Arch Intern Med. 2011; 171: 1463-1468.

    Article  PubMed  Google Scholar 

  8. Schwartz LM, Woloshin S. The Drug Facts Box: Improving the communication of prescription drug information. Proc Natl Acad Sci U S A. 2013; 110(Suppl 3): 14069-14074.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Schwartz LM, Woloshin S, Welch HG. The drug facts box: Providing consumers with simple tabular data on drug benefit and harm. Med Decis Making: An Int J Soc Med Decis Mak. 2007; 27: 655-662.

    Article  Google Scholar 

  10. Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: Two randomized trials. Ann Intern Med. 2009; 150: 516-527.

    Article  PubMed  Google Scholar 

  11. Woloshin S, Schwartz LM. The new weight-loss drugs, Lorcaserin and Phentermine-Topiramate: Slim pickings? JAMA Internal Medicine. 2014. doi:10.1001/jamainternmed.2013.14629.

    Google Scholar 

  12. Woloshin S, Schwartz LM, Welch HG. The value of benefit data in direct-to-consumer drug ads. Health affairs Suppl Web Exclusives. 2004; W4: 234-245.

    Google Scholar 

  13. O'Donoghue AC, Sullivan HW, Aikin KJ. Randomized study of placebo and framing information in direct-to-consumer print advertisements for prescription drugs. Ann Behav Med. 2014. doi:10.1007/s12160-01409603-1.

Download references

Author’s Statement of Conflict of Interest

Lila J. Finney Rutten declares that she has no conflict of interest.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Lila J. Finney Rutten Ph.D., M.P.H..

About this article

Cite this article

Rutten, L.J.F. Leveraging Health Communication Research to Inform Regulation of Direct-to-Consumer Ads for Prescription Medications: a Comment on O’Donoghue et al.. ann. behav. med. 48, 291–292 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI:


  • Placebo
  • Prescription Medication
  • Patient Engagement
  • Communication Factor
  • Accurate Perception